Armata Pharmaceuticals, Inc.
ARMP- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000921114
No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Armata Pharmaceuticals, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −3 vs. Q4 2022
- Shares held
- 1.23M
- −68.7K (−5.3%) vs. Q4 2022
- Total value
- $2.06M
- +$447.9K (+27.8%) vs. Q4 2022
- New holders
- 2
- 2 more added
- Sold out
- 5
- 7 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARMP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 53 | $32.3M |
| Q1 2026 | 45 | $40.2M |
| Q4 2025 | 36 | $7.85M |
| Q3 2025 | 28 | $2.27M |
| Q2 2025 | 29 | $1.40M |
| Q1 2025 | 26 | $1.08M |
| Q4 2024 | 24 | $2.57M |
| Q3 2024 | 24 | $3.28M |
| Q2 2024 | 23 | $3.86M |
| Q1 2024 | 24 | $5.93M |
| Q4 2023 | 25 | $4.17M |
| Q3 2023 | 23 | $3.85M |
| Q2 2023 | 22 | $1.35M |
| Q1 2023 | 23 | $2.06M |
| Q4 2022 | 26 | $1.61M |
| Q3 2022 | 20 | $5.73M |
| Q2 2022 | 19 | $5.25M |
| Q1 2022 | 20 | $6.61M |
| Q4 2021 | 17 | $7.25M |
| Q3 2021 | 20 | $4.32M |
| Q2 2021 | 21 | $4.59M |
| Q1 2021 | 23 | $5.62M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Armata Pharmaceuticals, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Householder Group Estate & Retirement Specialist, LLC | 136 | $0 | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 200 | $0 | 0.00% | +200 | New |
| Morgan Stanley | 2 | $3 | 0.00% | −12−85.7% | Reduced |
| Wells Fargo & Company | 75 | $126 | 0.00% | 00.0% | Unchanged |
| Salem Investment Counselors Inc | 100 | $167 | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 571 | $954 | 0.00% | 00.0% | Unchanged |
| Trifecta Capital Advisors, LLC | 714 | $1.19K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,143 | $5.00K | 0.00% | −4,032−56.2% | Reduced |
| UBS Group AG | 4,002 | $6.68K | 0.00% | −2,916−42.2% | Reduced |
| Millennium Management LLC | 11,130 | $19.0K | 0.00% | −4,455−28.6% | Reduced |
| Dimensional Fund Advisors LP | 11,472 | $19.2K | 0.00% | 00.0% | Unchanged |
| Captrust Financial Advisors | 13,548 | $22.6K | 0.00% | +13,548 | New |
| SeaCrest Wealth Management, LLC | 18,130 | $30.3K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 19,380 | $32.4K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 22,463 | $37.5K | 0.00% | 00.0% | Unchanged |
| Ergoteles LLC | 24,585 | $41.1K | 0.00% | −3,356−12.0% | Reduced |
| BlackRock Inc. | 25,368 | $42.4K | 0.00% | +816+3.3% | Added |
| HRT Financial LP | 31,194 | $52.0K | 0.00% | −11,083−26.2% | Reduced |
| Vanguard Group Inc | 57,182 | $95.5K | 0.00% | +13,387+30.6% | Added |
| Renaissance Technologies LLC | 63,196 | $106.0K | 0.00% | −10,500−14.2% | Reduced |
| Edgewood Management LLC | 100,000 | $167.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 193,682 | $323.4K | 0.01% | 00.0% | Unchanged |
| Bank of America Corp | 634,444 | $1.06M | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −20,024−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −13,907−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −12,162−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −10,247−100.0% | Sold out |
| U.S. Capital Wealth Advisors, LLC | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |